Safety assessment of EPA-rich oil produced from yeast: Results of a 90-day subchronic toxicity study

MacKenzie, Susan A.; Belcher, Leigh A; Sykes, Greg P.; Frame, Steven R.; Mukerji, Pushkor; Gillies, Peter J.

doi:10.1016/j.yrtph.2010.08.021

Cited by 19 publications

(14 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The safety profile of the EPA oil in these tests was comparable to a commercial fish oil. In addition, the safety of EPA oil produced from the GM Y. lipolytica yeast was evaluated following 90 d of exposure in a study by MacKenzie et al (2010). Groups of rats received 0 (olive oil), 98, 488 or 976 mg EPA kg À1 day À1 , or GRAS fish oil or deionized water by oral gavage.…”

Section: Safety Studies On Yarrowia and Yarrowia-derived Productsmentioning

confidence: 99%

Yarrowia lipolytica: Safety assessment of an oleaginous yeast with a great industrial potential

Groenewald

Boekhout

Neuvéglise

et al. 2013

Critical Reviews in Microbiology

397

288

View full text Add to dashboard Cite

Yarrowia lipolytica has been developed as a production host for a large variety of biotechnological applications. Efficacy and safety studies have demonstrated the safe use of Yarrowia-derived products containing significant proportions of Yarrowia biomass (as for DuPont's eicosapentaenoic acid-rich oil) or with the yeast itself as the final product (as for British Petroleum's single-cell protein product). The natural occurrence of the species in food, particularly cheese, other dairy products and meat, is a further argument supporting its safety. The species causes rare opportunistic infections in severely immunocompromised or otherwise seriously ill people with other underlying diseases or conditions. The infections can be treated effectively by the use of regular antifungal drugs, and in some cases even disappeared spontaneously. Based on our assessment, we conclude that Y. lipolytica is a ''safe-to-use'' organism.

show abstract

Section: Safety Studies On Yarrowia and Yarrowia-derived Productsmentioning

confidence: 99%

Yarrowia lipolytica: Safety assessment of an oleaginous yeast with a great industrial potential

Groenewald

Boekhout

Neuvéglise

et al. 2013

Critical Reviews in Microbiology

397

288

View full text Add to dashboard Cite

show abstract

“…The SCO that has heretofore been missing from commerce is an EPArich oil with little to no DHA. This changed with the recent introduction of New Harvest (DuPont Applied BioSciences, Wilmington, DE), an oil derived from a genetically modified yeast (Yarrowia lipolytica) that contains approximately 35% EPA [8]. The availability of SCO providing EPA or DHA, now allows dietary supplement manufacturers the flexibility to offer defined mixtures of EPA:DHA ranging from 1:0 to 0:1 and everything in between in a natural triglyceride form.…”

Section: Personal Nutritionmentioning

confidence: 99%

“…As such, there is now a pressing need for new and novel sources of long-chain omega-3 fatty acids to help consumers achieve dietary sufficiency pursuant to current recommendations. Biotechnology has recently enabled the development of several non-marine oils enriched in omega-3 fatty acids that can be used in foods and dietary supplements [7][8][9]; the fatty acid composition of some of these new oils is presented in Table 1 and compared to that of conventional fish oil.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Omega-3 Fatty Acids in Food and Pharma: The Enabling Role of Biotechnology

Gillies

Harris

Kris-Etherton

2011

Curr Atheroscler Rep

Self Cite

View full text Add to dashboard Cite

Omega-3 fatty acid research, which began as an epidemiologic curiosity, has generated perhaps the strongest dataset for any nutrient in regard to cardiovascular disease risk reduction. Although once a relatively descriptive field, advances in analytic techniques have opened up the biochemistry of omega-3 fatty acids and nutritional genomics in plants and man and have taken the field into the "omic" era. Despite this progress, fundamental questions remain unanswered, such as which fatty acid or metabolite thereof drives a given health benefit, how much of a given fatty acid should we consume, and how do we best source the requisite fatty acids? Of these questions, the ability to source omega-3 fatty acids in order to meet dietary guidelines has become a practical concern. The advent of novel oils from plants and single cell organisms as enabled by biotechnology may provide a solution to this problem and in the process open up new uses for omega-3 fatty acids in dietary supplements and drugs.

show abstract

“…The EPA-enriched oil from Y. lipolytica has been marketed under the brand name NewHarvest™ Omega-3. The safety profile of EPA-enriched oil is comparable to that of fish oil [27,28]. Furthermore, this source of EPA is free of environmental contaminants.…”

Section: Bioengineering Of Yarrowia Lipolytica For Omega-3 Fatty Acidmentioning

confidence: 98%

Metabolic engineering for the production of clinically important molecules: Omega‐3 fatty acids, artemisinin, and taxol

Bhatia

2011

Biotechnology Journal

View full text Add to dashboard Cite

Driven by requirements for sustainability as well as affordability and efficiency, metabolic engineering of plants and microorganisms is increasingly being pursued to produce compounds for clinical applications. This review discusses three such examples of the clinical relevance of metabolic engineering: the production of omega-3 fatty acids for the prevention of cardiovascular disease; the biosynthesis of artemisinic acid, an anti-malarial drug precursor, for the treatment of malaria; and the production of the complex natural molecule taxol, an anti-cancer agent. In terms of omega-3 fatty acids, bioengineering of fatty acid metabolism by expressing desaturases and elongases, both in soybeans and oleaginous yeast, has resulted in commercial-scale production of these beneficial molecules. Equal success has been achieved with the biosynthesis of artemisinic acid at low cost for developing countries. This is accomplished through channeling the flux of the isoprenoid pathway to the specific genes involved in artemisinin biosynthesis. Efficient coupling of the isoprenoid pathway also leads to the construction of an Escherichia coli strain that produces a high titer of taxadiene-the first committed intermediate for taxol biosynthesis. These examples of synthetic biology demonstrate the versatility of metabolic engineering to bring new solutions to our health needs.

show abstract

Safety assessment of EPA-rich oil produced from yeast: Results of a 90-day subchronic toxicity study

Cited by 19 publications

References 21 publications

Yarrowia lipolytica: Safety assessment of an oleaginous yeast with a great industrial potential

Yarrowia lipolytica: Safety assessment of an oleaginous yeast with a great industrial potential

Omega-3 Fatty Acids in Food and Pharma: The Enabling Role of Biotechnology

Metabolic engineering for the production of clinically important molecules: Omega‐3 fatty acids, artemisinin, and taxol

Contact Info

Product

Resources

About